The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Takeda
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Merck; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
Jayesh Desai
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Swaminathan Padmanabhan Iyer
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Incyte (Inst); Novartis (Inst); Takeda (Inst)
 
Shirish M. Gadgeel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; Genentech/Roche
 
Suresh S. Ramalingam
No Relationships to Disclose
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Lilly; Merck; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Patricia LoRusso
Leadership - Agios; Five Prime Therapeutics; Halozyme; Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; CytomX Therapeutics; Genentech; Genentech; Genmab; Glenmark; Ignyta; Menarini; Novartis; Omniox; Takeda
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Gaurav Bajaj
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Georgia Kollia
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Other Relationship - Bristol-Myers Squibb
 
Zhenhao Qi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shashwati Basak
No Relationships to Disclose
 
Bruce S. Fischer
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Matti Davis
Employment - Ayala Pharmaceuticals
Stock and Other Ownership Interests - OncoMed
Travel, Accommodations, Expenses - Ayala Pharmaceuticals
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)